• LAST PRICE
    0.9900
  • TODAY'S CHANGE (%)
    Trending Down-0.1100 (-10.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    1.1100 / 1.1000
  • Day Range
    Low 0.9400
    High 1.1100
  • 52 Week Range
    Low 0.9400
    High 10.9000
  • Volume
    12,135
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 1.1
TimeVolumeELOX
09:32 ET3101.1
09:44 ET9001.1
10:18 ET5001.1
11:43 ET1001.1
12:01 ET1001.09
12:35 ET11001.1
12:39 ET10001.09
12:53 ET10001.09
02:03 ET2001.092
02:39 ET1201.085
02:43 ET3001.08
03:10 ET3001.03
03:12 ET46550.94
03:55 ET10000.99
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesELOX
Eloxx Pharmaceuticals Inc
3.5M
-0.1x
---
United StatesENVB
Enveric Biosciences Inc
3.5M
-0.1x
---
United StatesREVB
Revelation Biosciences Inc
3.3M
-1.4x
---
United StatesGBLX
GB Sciences Inc
3.2M
-0.7x
---
United StatesCYCC
Cyclacel Pharmaceuticals Inc
3.7M
-0.1x
---
United StatesVRAX
Virax Biolabs Group Ltd
3.2M
-1.1x
---
As of 2023-12-07

Company Information

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the science of ribosome modulation, leveraging both its TURBO- ZM chemistry technology platform and its library of aminoglycosides to develop oral small-molecule ribosome modulating agents (RMAs) and eukaryotic ribosome selective glycosides (ERSGs) for the treatment of rare and ultra-rare genetic diseases. Its lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. The Company is also advancing ZKN-013 as an oral agent for the treatment of recessive dystrophic (RDEB)/ junctional epidermolysis bullosa (JEB) and familial adenomatous polyposis (FAP) patients with nonsense mutations. The Company also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, as well as rare ocular genetic disorders.

Contact Information

Headquarters
480 ARSENAL WAY, SUITE 130WATERTOWN, MA, United States 02472
Phone
781-577-5300
Fax
302-636-5454

Executives

Independent Chairman of the Board
Tomer Kariv
President, Chief Executive Officer, Director
Sumit Aggarwal
Interim Chief Financial Officer
Daniel Geffken
Independent Director
Lindsay Androski
Independent Director
Steven Rubin

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$3.5M
Revenue (TTM)
$0.00
Shares Outstanding
3.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.70
EPS
$-9.06
Book Value
$-4.92
P/E Ratio
-0.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.